Call Girls Siliguri Just Call 8250077686 Top Class Call Girl Service Available
EASO2011 PanArab 1 Azim
1. BREAST CANCER DURING PREGNANCY What evidence do we have? Hatem A.Azim Jr Breast Cancer Translational Research Laboratory (BCTL) Institut Jules Bordet (IJB) Brussels, Belgium 11 th Pan Arab Cancer Congress; EASO session Casablanca; April 29 – May 1 st , 2011
2. Berry DL et al; JCO 1999 EPIDEMIOLOGY 1/3.000 pregnancies 5-10% of breast cancer < 40 y ~ 10,000 cases/year worldwide
10. Age at diagnosis 33 y (24-45) Gestational age at diagnosis W 17 (2-33) Gestation age of starting chemo W 23 (14-33) Histological grade III 82% ER –ve 70% Her-2/neu +ve 30% Number of cycles 4 (1-6) Method of delivery Vaginal 60% Cesarean 40% MD Anderson - experience
11.
12.
13.
14. Age at diagnosis 37 y (23-42) Gestation age of starting chemo W 19 (16-30) Node +ve 60% ER –ve 50% Her-2/neu +ve 20% Number of weeks 12 (4-16) Method of delivery Vaginal 40% Cesarean 60% IEO – experience
15.
16. MD Anderson (57) IEO (20) FAC Regimen Weekly epirubicin 37 W Gestational age at delivery 35 W 2/57 (4%) Pre-term pregnancies 1/20 (5%) 3/57 Congenital anomalies 1/20 Maternal outcome at 38m 70% DFS 70% 77% OS 85%
17.
18.
19. Long-term effects of in-utero exposure to doxorubicin-based regimens Aviles A et al; Ann Oncol 2006 Hahn K et al; Cancer 2006 Median FU Number Late effects Doxorubicin-based regimens (leukemia/lymphoma) 18 Y 89 None FAC (CI Doxo) 6 Y 18 None
20. Long-term effects of in-utero exposure to weekly epirubicin (n=30) Updated Peccatori F et al; Breast Ca Res Treat 2009 Normal Development !! Age 0-1 Age 2-3 Age 4-5 Age 6-7 Age 8 N° 5 10 9 3 3
23. Transplacental transfer of chemotherapy in baboon models * % during the first 25h from maternal exposure Van Calsteren V et al; Gynecol Oncol 2010 Van Calsteren V et al; Int J Gynecol Cancer 2010 Drug % in fetus * Total No. (Detected) Doxorubicin 7.5 ± 3.2 15 ( 6) Epirubicin 4.0 ± 1.6 11 (8) Paclitaxel 1.4 ± 0.8 11 (7) Docetaxel 0 9 (0) Cyclophosphamide 25.1 ± 6.3 4 (3) Carboplatin 57.5 ± 14.2 7 (7)
24.
25.
26.
27.
28. HER2 plays a pivotal role in the development of different foetal organs LUNG KIDNEY INTESTINE SKIN Patel NV et al; Am J Respirol Mol Biol 2000 Kokai Y et al; PNAS 1987
29.
30. A: adjuvant; M: metastatic; T: trastuzumab; NS: not significant; pre: preconception; EF: ejection fraction; IUGR: intrauterine growth restriction; vag blee: vaginal bleeding; PROM; premature rupture of membranes; NAD: no abnormality detected; RF: renal failure; Resp F: respiratory failure Setting Regimen Time Mother Pregnancy Baby Watson 2005 A T Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M T+ vinorelbine 3 rd NS NS NAD Waterston 2006 A T Pre NS NS NAD Bader 2007 M T + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M T Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M T + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M T Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A T Pre NS Ectopic preg., E. Aborton … Pant 2008 M T Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M T Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A T + tam + LHRH Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A T + tam Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Resp F, Death 2) Transient Resp. F Azim Jr 2009 A T Pre NS NS NAD Goodyer 2009 M A T T 2 nd , Pre None None Premature
31. Setting Regimen Time Mother Pregnancy Baby Watson 2005 A Herceptin Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M Herceptin + vinorelbine 3 rd NS NS NAD Waterston 2006 A Herceptin Pre NS NS NAD Bader 2007 M Herceptin + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M Herceptin Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M Herceptin + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A Herceptin Pre NS Ectopic preg., E. Aborton … Pant 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M Herceptin Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A Herceptin + tamoxifen + gasorelin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A Herceptin + tamoxifen Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Res. F, Death 2) Transient Res. F Azim Jr 2009 A Herceptin Pre NS NS NAD
32.
33. Setting Regimen Time Mother Pregnancy Baby Watson 2005 A Herceptin Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M Herceptin + vinorelbine 3 rd NS NS NAD Waterston 2006 A Herceptin Pre NS NS NAD Bader 2007 M Herceptin + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M Herceptin Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M Herceptin + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A Herceptin Pre NS Ectopic preg., E. Aborton … Pant 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M Herceptin Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A Herceptin + tamoxifen + gasorelin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A Herceptin + tamoxifen Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Res. F, Death 2) Transient Res. F Azim Jr 2009 A Herceptin Pre NS NS NAD
34. Setting Regimen Time Mother Pregnancy Baby Watson 2005 A Herceptin Pre, 1 st , 2 nd NS Anhydramnios NAD Fanale 2005 M Herceptin + vinorelbine 3 rd NS NS NAD Waterston 2006 A Herceptin Pre NS NS NAD Bader 2007 M Herceptin + paclitaxel 2 nd NS Anhydramnios, IUGR Transient Resp F,RF Shrim 2007 M Herceptin Pre, 1 st , 2 nd EF decrease NS Transient RF Sekar 2007 M Herceptin + docetaxel 2 nd , 3 rd NS Anhydramnios NAD Witzel 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios, vag blee Resp F, died Berveiller 2008 A Herceptin Pre NS Ectopic preg., E. Aborton … Pant 2008 M Herceptin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios NAD Weber 2008 M Herceptin Pre, 1 st , 2 nd NS Anhydramnios Resp F, died Warraich 2009 A Herceptin + tamoxifen + gasorelin Pre, 1 st , 2 nd , 3 rd NS Anhydramnios Res. F, fetal death after 40 minutes Beale 2009 A Herceptin + tamoxifen Pre, 1 st , 2 nd NS Anhydramnios, PROM Twins: 1) RF, Res. F, Death 2) Transient Res. F Azim Jr 2009 A Herceptin Pre NS NS NAD
49. ABORTION DOES NOT IMPROVE PROGNOSIS Unpublished data Full-term delivery (n=24) Abortion/anticipated delivery (n=38) Log-rank p=0.03
50. INFERIOR DFS AT MEDIAN FU 4 YEARS Unpublished data Disease free survival (DFS) Overall survival (OS) Log-rank p:0.01 HR 2.3 (95% CI 1.3-4.2)* * Adjusted for T, N, age, HER2, ki67, perivascular invasion Log-rank p:0.17 HR 1.7 (95% CI 0.8-3.9)* BCP BCP Controls Controls
51.
52. Elective Systemic therapy in pregnancy Summary Consider weekly application Anthracycline-based regimen √ Taxanes 2 nd best Trastuzumab X Tamoxifen X Bisphosphonates Better postponed
